Literature DB >> 12142395

Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course.

Thomas Schöndorf1, Markus Hoopmann, Mathias Warm, Rainer Neumann, Anke Thomas, Uwe-Jochen Göhring, Carsten Eisberg, Peter Mallmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12142395

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  6 in total

Review 1.  Challenges in the clinical utility of the serum test for HER2 ECD.

Authors:  Lian Lam; Nicholas McAndrew; Marla Yee; Ting Fu; Julia C Tchou; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2012-04-03

2.  Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients.

Authors:  Patricia Diana Sørensen; Erik Hugger Jakobsen; Jonna Skov Madsen; Eva Brix Petersen; Rikke Fredslund Andersen; Birthe Østergaard; Ivan Brandslund
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-13       Impact factor: 4.553

3.  Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation.

Authors:  I Abdel Salam; H E Gaballa; N Abdel Wahab
Journal:  Med Oncol       Date:  2008-12-18       Impact factor: 3.064

4.  Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.

Authors:  Tanja Fehm; Sven Becker; Silke Duerr-Stoerzer; Karl Sotlar; Volkmar Mueller; Diethelm Wallwiener; Nancy Lane; Erich Solomayer; Jonathan Uhr
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

5.  HER-2/neu diagnostics in breast cancer.

Authors:  Walter P Carney; Kim Leitzel; Suhail Ali; Rainer Neumann; Allan Lipton
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

6.  Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer.

Authors:  Sae Byul Lee; Jong Won Lee; Jong Han Yu; Beom Seok Ko; Hee Jeong Kim; Byung Ho Son; Gyungyub Gong; Hee Jin Lee; Sung-Bae Kim; Kyung Hae Jung; Jin-Hee Ahn; Woochang Lee; Joohon Sung; Sei-Hyun Ahn
Journal:  BMC Cancer       Date:  2014-12-10       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.